ABAshley Brown

Ashley Brown

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ashley Brown has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sensitivity Analysis of Hepatitis B and C Mortality in England Using Data Linkage: Meeting the WHO Elimination Threshold for Mortality

    by Annabel A. Powell, Annastella Costella, Rachel Roche, David Leeman, Ashley Brown, Beatrice Emmanouil, Mark Gillyon‐Powell, Ross Harris, Holly D. Mitchell, Ruth Simmons, et al.

    The United Kingdom, along with many other countries, is working towards eliminating viral hepatitis as a public health threat by 2030, with a combined mortality target of less than or equal to six deaths per 100,000 population. The current methodology of reporting uses death registrations alone, which has been estimated to underestimate mortality rates by up to 60% for hepatitis C (HCV)‐related liver disease. We aim to conduct a sensitivity analysis using data linkage of death certificates, hepatitis B (HBV) and HCV diagnoses and admissions for end‐stage liver disease (ESLD) and/or hepatocellular carcinoma (HCC) to estimate mortality rates, assess progress towards elimination and evaluate underreporting. Between 2000 and 2023, 7967 deaths were reported due to HBV‐ and/or HCV‐associated ESLD and/or HCC. Using data linkage of all three datasets, this increased to 11,487, with underreporting estimated to be 37% overall. The upper bound combined mortality rate was estimated to be 1.3 deaths per 100,000 population at its peak in 2015, therefore surpassing the WHO target for all years evaluated. From 2015 to 2023, both HCV‐associated ESLD and/or HCC mortality decreased (1.12 to 0.88 deaths per 100,000 population), however, there was a slight increase for HBV‐associated ESLD and/or HCC deaths during the same time frame (0.3 to 0.35). A higher proportion of HBV‐related deaths were in males (p < 0.05) who died outside London (p < 0.05) and a lower proportion were White (p < 0.05) when compared to HCV‐related deaths. While England has met the WHO impact targets, it is important we continue to drive reductions in mortality.


  • Open Access

    Consistent high prevalence of undiagnosed blood‐borne virus infection in patients attending large urban emergency departments in England

    by Mark J. Hopkins, Stacy Todd, Mike Beadsworth, Charlotte Anderson, Zameer Mohamed, David Muir, Roberto Vivancos, Ashley S. Brown, Murad Ruf, Anu Chawla

    Innovative care pathways including case finding and linkage to care are crucial to achieve the World Health Organization targets for the elimination of viral hepatitis.(1) In England there were over 23.4 million attendances at Emergency departments (EDs) in 2016‐17 representing a significant opportunity to engage for case finding.(2) EDs may be the only healthcare access point for some marginalised groups including recent migrants, homeless, or people who inject drugs. Seroprevalence studies have been used in the USA to guide public health interventions where large scale, integrated ED testing and linkage programs are increasingly common.(3) Since 2008 routine opt‐out testing for HIV in UK ED settings has been recommended for those in high prevalence areas (>0.2%).


  • Open Access

    IDDF2019-ABS-0136 Sofosbuvir/velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis

    by Sergio Borgia, Janet Dearden, Yoav Lurie, Stephen Shafran, Ashley Brown, Robert Hyland, Sophia Lu, Svetlana Markova, Hadas Dvory-Sobol, Anu Osinusi, et al.

    Background Approved HCV treatments for patients on dialysis are associated with complexities including drug-drug interactions, baseline resistance testing and use of ribavirin. Despite higher concentrations of the primary circulating sofosbuvir (SOF) metabolite, GS-331007, in severe renal impairment, real-world cases demonstrated substantial use of SOF-based regimens in this population without safety concerns identified. This study evaluated the safety, efficacy, and pharmacokinetics (PK) of SOF/velpatasvir (VEL) for 12 weeks in patients with HCV infection on dialysis. Methods Treatment-naive or -experienced patients, of any genotype, with or without compensated cirrhosis undergoing hemodialysis or peritoneal dialysis, were enrolled to receive open-label SOF/VEL (400/100 mg) once daily for 12 weeks. The primary efficacy endpoint was a comparison of the SVR12 to a prespecified historic control rate of 83%. The primary safety endpoint was the proportion of patients who discontinued therapy due to adverse events (AEs). Secondary endpoints included safety, viral resistance and PK. Results 59 patients were enrolled at 21 sites in Canada, United Kingdom, Spain, Israel, Australia and New Zealand. The median age was 62 years (range 49–86), 59% were male, 53% white, 32% treatment experienced, 29% had cirrhosis. Most patients had HCV genotype 1 (42%), or 3 (27%). Most (92%) were on hemodialysis with a mean dialysis duration of 7.3 years. Treatment was well tolerated; no one discontinued therapy due to AEs. One patient was discontinued therapy on day 74 for non-compliance with 48% study medication adherence by pill count. Overall, 56/59 (95%) of patients achieved SVR12. Two (3%) had virologic relapse (one with non-adherence). One patient did not achieve SVR12 due to death from suicide after SVR4. Exposures were consistent with the Phase 1 renal impairment study. The most frequent AEs were headache, fatigue, nausea, and vomiting. Serious AEs occurred in 19% of patients, none was assessed as related to study drug. Conclusions Treatment with SOF/VEL for 12 weeks in patients with and without cirrhosis undergoing dialysis resulted in a 95% SVR12 rate. The regimen was safe and well-tolerated with no treatment-related discontinuations or treatment-related SAEs.


  • Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C‐SCAPE study

    by A. Brown, C. Hézode, E. Zuckerman, G. R. Foster, A. Zekry, S. K. Roberts, F. Lahser, C. Durkan, C. Badshah, B. Zhang, et al.

    Summary: People with hepatitis C virus (HCV) infection other than genotype 1 represent a heterogeneous group. The aim of the phase 2 C‐SCAPE study was to evaluate elbasvir/grazoprevir (EBR/GZR), with or without ribavirin (RBV), in participants with HCV genotype 2, 4, 5 or 6 infection. This was a part randomised, open‐label, parallel‐group study (NCT01932762; PN047‐03) of treatment‐naive, noncirrhotic participants. Participants with HCV genotype 2 infection received GZR 100 mg + RBV ± EBR 50 mg for 12 weeks and those with genotype 4, 5 or 6 infection were randomized to receive EBR/GZR ± RBV for 12 weeks. The primary endpoint was sustained virological response 12 weeks after completion of treatment (SVR12; HCV RNA <25 IU/mL). Among participants with genotype 2 infection, SVR12 was achieved by 80% (24/30) of those receiving EBR/GZR + RBV and 73% (19/26) of those receiving GZR + RBV. SVR rates were high in participants with HCV genotype 4 infection receiving EBR/GZR with and without RBV (100% [10/10] and 90% [9/10]; respectively). In contrast, the addition of RBV to EBR/GZR appeared to increase SVR12 in participants with genotype 5 infection (EBR/GZR, 25%; EBR/GZR + RBV 100% [4/4]). In participants with genotype 6 infection, SVR12 was 75% (3/4) in both those receiving EBR/GZR and those receiving EBR/GZR + RBV. The safety profile was similar across treatment arms, with adverse events tending to occur more frequently among participants receiving RBV. In conclusion, these data support the inclusion of participants with genotype 4 or 6 infection in the EBR/GZR phase 3 studies. EBR/GZR ± RBV was unsatisfactory for participants with genotype 2 or 5 infection.


  • Simeprevir and daclatasvir for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1b and advanced liver disease

    by Christophe Hézode, Piero L. Almasio, Stefan Bourgeois, Peter Buggisch, Ashley Brown, Moises Diago, Yves Horsmans, Lawrence Serfaty, Ferenc Szalay, Giovanni B. Gaeta, et al.

    Background & Aims: We investigated the efficacy and safety of simeprevir plus daclatasvir in treatment‐naïve patients with chronic, genotype 1b hepatitis C virus infection and advanced liver disease, excluding patients with pre‐defined NS5A resistance‐associated substitutions.Methods: This phase II, open‐label, single‐arm, multicentre study included patients aged ≥18 years with advanced fibrosis or compensated cirrhosis (METAVIR F3/4). Patients with NS5A‐Y93H or L31M/V resistance‐associated substitutions at screening were excluded. Simeprevir (150 mg)+daclatasvir (60 mg) once daily was administered for 12 or 24 weeks; treatment could be extended to 24 weeks prior to or at the Week 12 visit. Primary efficacy endpoint was sustained virological response 12 weeks after the end of treatment.Results: A total of 106 patients were treated; 27% patients were aged >65 years, 39% had cirrhosis, 53% had estimated glomerular filtration rate 30‐89 mL/min, 14% had diabetes, and 38% had arterial hypertension. Overall, 42/106 received 12 weeks of treatment and 64/106 received 24 weeks of treatment. Ninety‐seven (92%) patients achieved a sustained virological response 12 weeks after the end of treatment. The reasons for failure were viral breakthrough (n=7) at weeks 4‐16, early treatment discontinuation (n=1) and viral relapse (n=1). Seventy‐four (70%) patients had ≥1 adverse event during treatment, including six (6%) patients with ≥1 serious adverse event. Three (3%) patients discontinued treatment owing to adverse events.Conclusions: Simeprevir+daclatasvir demonstrated strong antiviral activity and was well‐tolerated in patients with hepatitis C virus genotype 1b infection, advanced liver disease and a high prevalence of comorbidities. However, viral breakthrough occurred in seven patients, making this regimen unsatisfactory.


  • PTH-107 Chronic Hepatitis B Management The UK: A National Survey of Current Practice Following Nice Guidance

    by N Hansi, P Troke, Us Gill, K Agarwal, M Aldersley, S Al-Shamma, A Brown, J Cobbold, P Collins, A Fowell, et al.

    Introduction National Institute for Health and Care Excellence (NICE) published guidance on the management of chronic hepatitis B (CHB) in June 2013 (NICE 165). Where antiviral therapy was indicated, NICE recommended 48 weeks Peg-interferon alfa-2a (PegIFNα) as first-line treatment in compensated disease and early discontinuation of PegIFNα based on stopping rules. Nucleos(t)ide analogues were recommended as second-line therapies. This survey was undertaken to capture current CHB practice management across the UK following NICE 165 and report PegIFNα use, and review the availability/utility of quantitative HBsAg. Methods This was a UK-wide national multicentre study, where 25 CHB treatment centres were invited to complete a qualitative questionnaire of CHB practice. Clinical practice in the 12 months preceding NICE 165 was compared with CHB management in the immediate 12 months post publication. Results All centres participating undertook a multi-disciplinary approach to the treatment of CHB patients, with 75% of centres adopting joint consultant-nurse led clinics. Interim analysis of the data revealed that 73% of centres consider PegIFNα as first line therapy in eAg+ disease, compared with 40% in eAg- disease. Importantly, there was no difference in the use of PegIFNα, irrespective of eAg status, prior to and following the publication of NICE 165 (p = 0.82). Of those patients treated with PegIFNα as first line-therapy, 63% of them, to date, required second line therapy with NUCs due to treatment failure. Conclusion This UK survey demonstrates that current practice has not significantly changed following NICE 165. While most centres adopt a multi-disciplinary approach, the UK guidance on CHB has not been widely adopted. Barriers to this may include the limited availablilty of qHBsAg in UK centres, but more likely this relates to Physician preference for the continued use of NUCs as first-line therapy of choice. Disclosure of Interest N. Hansi: None Declared, P. Trok, None Declared, U. Gill: None Declared, K. Agarwal: None Declared, M. Aldersley: None Declared, S. Al-Shamma: None Declared, A. Brown: None Declared, J. Cobbold: None Declared, P. Collins: None Declared, A. Fowell: None Declared, W. Gelson: None Declared, A. Holt: None Declared, S. McPherson: None Declared, M. Phillips: None Declared, M. Prince: None Declared, P. Richardson: None Declared, S. Ryder: None Declared, S. Singhal: None Declared, B. Stone: None Declared, A. Ustianowski: None Declared, J. Vilar: None Declared, L. Walker: None Declared, T. Wong: None Declared, P. Kennedy Grant/research support from: Gilead Sciences

  • Open Access

    Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

    by Graham R. Foster, Stephen Pianko, Ashley Brown, Daniel Forton, Ronald G. Nahass, Jacob George, Eleanor Barnes, Diana M. Brainard, Benedetta Massetto, Ming Lin, et al.


  • Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs

    by Ashley Brown, Zachary Goodman

    Hepatitis B virus (HBV) infection currently accounts for approximately 600,000 deaths per year resulting from progression of liver fibrosis to cirrhosis and hepatocellular carcinoma. Treatment of chronic hepatitis B with antiviral agents aims to improve survival through the reduction of HBV DNA to undetectable levels and the resultant prevention of disease progression. In recent years, observations in various disease areas have shown that liver fibrosis can be reversed if the underlying cause of the liver damage is effectively addressed. In line with these observations, there is now considerable evidence to suggest that effective sustained suppression of HBV replication with long-term anti-HBV treatment can result in measurable improvements in liver fibrosis over time, even in patients with advanced cirrhosis. This review article provides an overview of currently available data on regression of fibrosis and cirrhosis in patients with chronic hepatitis B treated with nucleoside and nucleotide analog inhibitors of HBV.


  • Open Access

    Liver transplantation for hepatocellular carcinoma

    by Sudeep Tanwar, Shahid A Khan, Vijay Paul Bob Grover, Catherine Gwilt, Belinda Smith, Ashley Brown

    Hepatocellular carcinoma (HCC) is the commonest primary malignancy of the liver. It usually occurs in the setting of chronic liver disease and has a poor prognosis if untreated. Orthotopic liver transplantation (OLT) is a suitable therapeutic option for early, unresectable HCC particularly in the setting of chronic liver disease. Following on from disappointing initial results, the seminal study by Mazzaferro et al in 1996 established OLT as a viable treatment for HCC. In this study, the “Milan criteria” were applied achieving a 4-year survival rate similar to OLT for benign disease. Since then various groups have attempted to expand these criteria whilst maintaining long term survival rates. The technique of living donor liver transplantation has evolved over the past decade, particularly in Asia, and published outcome data is comparable to that of OLT. This article will review the evidence, indications, and the future direction of liver transplantation for liver cancer.